Insulet Co. (NASDAQ:PODD) Shares Purchased by Principal Financial Group Inc.

Principal Financial Group Inc. raised its holdings in Insulet Co. (NASDAQ:PODD – Get Rating) by 561.1% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 59,139 shares of the medical instruments supplier’s stock after purchasing an additional 50,194 shares during the period. Principal Financial Group Inc. owned about 0.09% of Insulet worth $17,410,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. Raymond James Financial Services Advisors Inc. raised its position in shares of Insulet by 5.9% during the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 3,365 shares of the medical instruments supplier’s stock valued at $896,000 after acquiring an additional 187 shares in the last quarter. MetLife Investment Management LLC bought a new position in Insulet during the first quarter valued at about $1,140,000. Synovus Financial Corp boosted its stake in Insulet by 12.4% during the first quarter. Synovus Financial Corp now owns 3,716 shares of the medical instruments supplier’s stock valued at $989,000 after buying an additional 410 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in Insulet by 1.3% during the first quarter. Dimensional Fund Advisors LP now owns 96,390 shares of the medical instruments supplier’s stock valued at $25,676,000 after buying an additional 1,232 shares in the last quarter. Finally, Vontobel Holding Ltd. boosted its stake in Insulet by 91.0% during the first quarter. Vontobel Holding Ltd. now owns 3,888 shares of the medical instruments supplier’s stock valued at $1,026,000 after buying an additional 1,852 shares in the last quarter.

Insulet Stock Performance

Shares of PODD stock opened at $306.55 on Tuesday. The company has a debt-to-equity ratio of 2.72, a current ratio of 3.47 and a quick ratio of 2.46. Insulet Co. has a fifty-two week low of $192.33 and a fifty-two week high of $335.91. The stock’s 50-day moving average is $317.05 and its two-hundred day moving average is $302.61. The firm has a market cap of $21.37 billion, a P/E ratio of 257.29, a PEG ratio of 6.41 and a beta of 0.80.

Insulet (NASDAQ:PODD – Get Rating) last issued its earnings results on Thursday, May 4th. The medical instruments supplier reported $0.23 earnings per share for the quarter, topping the consensus estimate of $0.09 by $0.14. Insulet had a return on equity of 17.29% and a net margin of 0.04%. The company had revenue of $358.10 million for the quarter, compared to analyst estimates of $330.21 million. During the same period in the prior year, the firm posted $0.40 EPS. The business’s revenue was up 21.2% compared to the same quarter last year. Analysts predict that Insulet Co. will post 1.34 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently weighed in on the company. Wolfe Research assumed coverage on Insulet in a research note on Thursday, January 26th. They set a “peer perform” rating for the company. Morgan Stanley upped their target price on Insulet from $320.00 to $325.00 and gave the company an “equal weight” rating in a report on Friday, February 24th. UBS Group upped their target price on Insulet from $328.00 to $360.00 in a report on Friday, May 5th. Piper Sandler upped their target price on Insulet from $340.00 to $360.00 in a report on Friday, May 5th. Finally, Robert W. Baird upped their target price on Insulet from $350.00 to $370.00 in a report on Friday, May 5th. Eight analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $330.00.

Insiders Place Their Bets

In other news, insider Charles Alpuche sold 4,000 shares of the stock in a transaction dated Tuesday, February 28th. The stock was sold at an average price of $278.82, for a total transaction of $1,115,280.00. Following the transaction, the insider now owns 45,584 shares of the company’s stock, valued at approximately $12,709,730.88. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, insider Charles Alpuche sold 4,000 shares of the stock in a transaction dated Tuesday, February 28th. The stock was sold at an average price of $278.82, for a total transaction of $1,115,280.00. Following the transaction, the insider now owns 45,584 shares of the company’s stock, valued at approximately $12,709,730.88. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Wayde D. Mcmillan sold 1,255 shares of the stock in a transaction dated Monday, April 3rd. The shares were sold at an average price of $318.31, for a total value of $399,479.05. Following the transaction, the chief financial officer now directly owns 22,865 shares in the company, valued at approximately $7,278,158.15. The disclosure for this sale can be found here. Insiders have sold a total of 32,656 shares of company stock valued at $9,819,174 in the last three months. Insiders own 0.80% of the company’s stock.

Insulet Company Profile

(Get Rating)

Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System, as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals.